Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 23, n° 2P1
pages 220-228 (août 1990)
Doi : 10.1016/0190-9622(90)70202-S
accepted : 14 November 1989
Clinical and laboratory studies

Photochemotherapy improves chronic cutaneous graft-versus-host disease

Beatrix Volc-Platzer, MD a, , Herbert Hönigsmann, MD a, b, Wolfgang Hinterberger, MD c, Klaus Wolff, MD a
Vienna, Austria 

*Reprint requests: Beatrix Volc-Platzer, MD, Department of Dermatology I, University of Vienna Medical School, Alserstrasse 4, A-1090 Vienna, Austria.

We have used oral psoralen photochemotherapy (PUVA) to treat four patients with chronic graft-versus-host disease of the skin, oral mucosa, and liver, who had responded only partially to long-term immunosuppressive therapy (prednisolone, cyclosporine, azathioprine). PUVA therapy was delivered to the entire skin but not to the oral mucosa, and immunosuppressive therapy was continued in all patients. Two patients' skin lesions improved considerably; the oral lesions healed and did not recur in one. Immunosuppressive therapy could be reduced in these two patients. One patient with sicca signs did not improve. One patient had to interrupt PUVA therapy because of side effects attributed to 8-methoxypsoralen (nausea and vomiting). No flare of acute cutaneous graft-versus-host disease was noted during PUVA therapy. Chronic graft-versus-host disease of the liver did not improve in any patient.

The full text of this article is available in PDF format.
a  From the Department of Dermatology I, University of Vienna.
b  From the Division of Photobiology, University of Vienna.
c  From the Department of Internal Medicine, University of Vienna.

Top of the page

© 1990  Published by Elsevier Masson SAS.